Laurus Labs Limited (NSE: LAURUSLABS) has unveiled robust financial results for the first half of FY 2027, showcasing a significant revenue of ₹4,233 crore, marking a 31% year-on-year growth. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹1,406 crore, reflecting a strong operational performance.

Strong Revenue and Margin Expansion

The company’s robust performance is driven by sustained growth in its Contract Development and Manufacturing Organization (CDMO) segment, which has seen commercial supplies and a steady momentum in its Affordable Medicines division. The gross margins expanded by over 3.3% points to 62.9%, supported by a healthy business segment mix.

Strategic Investments

Laurus Labs Limited has also announced strategic investments in two technology platforms to bolster its Integrated CDMO offering. The company has entered into a definitive agreement to acquire a 60% stake in Galenvs, a specialized firm in Oligonucleotide and Precision Magnetic Nanoparticles for purification. This acquisition aims to expand Laurus’s position in the fast-growing Oligo market, which is projected to reach $11 billion by 2030, with a CAGR of 22-24%.

Additionally, Laurus Labs plans to acquire a 52% stake in SI &C Resins, a company with expertise in peptide/polymer chemistry. This acquisition will enhance the company’s manufacturing competitiveness and reliability, particularly in the rapidly expanding GLP-1 and non-GLP-1 peptide drugs market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Laurus Labs Limited

Laurus Labs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Laurus gains 34.7% over three months and trades near its 52-week highs. The PEG stands at 25.45 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 98% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 34.7% in three months. Yet revenue grows at only 3.8% and the PEG stands at 25.45. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Laurus Labs Limited.

Senores Pharmaceuticals Limited (SENORES) announced its unaudited financial results for the quarter and half year ended 30th September 2026, showcasing robust financial and operational performance. The company reported a 25% year-on-year increase in revenue for Q2 FY27 and a 38% rise in EBITDA, marking consistent strong growth across its businesses.

Segmental Highlights

The company’s revenue for Q2 and H1 FY27 grew by 25% and 30% respectively on a year-on-year basis. Notably, the Regulated Markets segment saw a 34% increase in revenue, while the Emerging Markets segment grew by 21% in Q2 and 25% in H1 FY27. The company’s portfolio in Regulated Markets nearly doubled, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, with 23 commercialized products.

Operational Excellence

Despite initial set-up and operating costs associated with Zoraya and Amerisyn, EBITDA for Q2 and H1 FY27 grew by 38% and 58% respectively, with margin expansion of approximately 290 bps and 530 bps on a year-on-year basis. The company’s cash from operations stood at ₹38 crores in H1 FY27, reflecting a consistent improvement in cash flow generation.

Forward-Looking Outlook

Senores Pharmaceuticals Limited remains optimistic about its future growth trajectory, on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. The company’s robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility underpin its positive outlook for the year and beyond.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Senores holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.33 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 159.1% and profits at 139.2% CAGR. Both numbers are exceptional. The stock holds at 69% of its 52-week range with RSI at 44. In other words, neither side has a clear edge right now. Both the business and the stock move in the right direction. Revenue grows at 159.1%, profits at 139.2%, and the PEG sits at 0.33 — below its growth rate. That combination is rare. Check Fundamentals of Senores Pharmaceuticals Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceutical company, announced on October 29, 2026, that it has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by the prestigious U.S.-based Science magazine. This recognition reflects Biocon’s long-standing reputation as an employer of choice in the global life sciences industry.

Recognition for Social Responsibility

Biocon was recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values. Shreehas Tambe, CEO and Managing Director, Biocon, said: “I am proud that Biocon has been recognized by Science magazine as one of the world’s Top 20 biopharmaceutical employers for the 15th consecutive year. This recognition reflects the talent, passion, and commitment of our people.”

People-Centric Culture

Biocon’s people-centric culture continues to be a key differentiator in strengthening its employer brand globally. Today, employees representing 37 nationalities across more than 60 cities worldwide contribute diverse perspectives and expertise to Biocon’s mission of delivering life-changing medicines to patients around the world.

As Biocon advances its ambition to become a fully integrated global medicines company, it remains committed to fostering a culture of innovation, excellence, and collaboration enabling it to make a meaningful difference to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.